Identification of a Non-Retinoid Opsin Ligand Through Pharmacophore-Guided Virtual Screening-A Novel Potential Rhodopsin-Stabilizing Compound.

Gian Carlo Demontis, Tiziano Tuccinardi, Marco Macchia, Miriana Di Stefano, Lisa Piazza, Clarissa Poles, Maria Ghilardi, Giulio Poli

Journal: Molecules (Basel, Switzerland) 2025;30(11):

PMID: 40509215

Abstract

Rhodopsin, a G-protein-coupled receptor (GPCR) comprising the protein opsin covalently linked to the chromophore 11-cis retinal, is pivotal in visual phototransduction. Mutations in the gene encoding rhodopsin (RHO) can cause opsin misfolding or reduce its stability, resulting in retinal degenerative disorders such as retinitis pigmentosa (RP). Current therapeutic strategies employing retinoid-based chaperones partially rescue the folding and trafficking of mutant rhodopsin, but are limited by inherent toxicity and instability due to photoinduced isomerization. In the present work, a pharmacophore-based virtual screening protocol combined with molecular docking and molecular dynamics simulations was employed, leading to the identification of a novel non-retinoid opsin ligand that can potentially act as a pharmacological chaperone. Biological validation confirmed that the compound binds opsin effectively, representing a valuable starting point for structure-based optimization studies aimed at identifying new opsin stabilizers.

Address: Department of Pharmacy, University of Pisa, 56126 Pisa, Italy.; Telethon Institute of Genetics and Medicine, 80078 Naples, Italy.; Genomics and Experimental Medicine Program, Scuola Superiore Meridionale (SSM, School of Advanced Studies), 80078 Naples, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.